Canada - English - Health Canada

sterimax inc - ceftazidime (ceftazidime pentahydrate) - powder for solution - 2g - ceftazidime (ceftazidime pentahydrate) 2g - third generation cephalosporins

Canada - English - Health Canada

sterimax inc - ceftazidime (ceftazidime pentahydrate) - powder for solution - 6g - ceftazidime (ceftazidime pentahydrate) 6g - third generation cephalosporins

Canada - English - Health Canada

sterimax inc - ceftazidime (ceftazidime pentahydrate) - powder for solution - 3g - ceftazidime (ceftazidime pentahydrate) 3g - third generation cephalosporins

Australia - English - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - ceftazidime pentahydrate, quantity: 2349 mg (equivalent: ceftazidime, qty 2000 mg) - injection, powder for - excipient ingredients: sodium carbonate - auro-ceftazidime is indicated for the treatment of single and mixed infections caused by susceptible aerobic organisms with suspected or documented resistance to other antimicrobials, but not to ceftazidime; as an alternative to aminoglycosides in pseudomonal infection in patients in whom aminoglycoside toxicity is a cause for concern and other antipseudomonal antibiotics cannot be used. . indications include the following.. severe infections in general. for example: septicaemia (including neonatal sepsis), bacteraemia; in patients in intensive care units with specific problems, e.g. infected burns.. respiratory tract. for example: pneumonia, bronchopneumonia, infected pleurisy, infected bronchiectasis and bronchitis.. severe ear, nose and throat infections. for example: otitis media, mastoiditis.. urinary tract. for example: acute and chronic pyelonephritis, pyelitis, cystitis, urethritis (bacterial only); infections associated with bladder and renal stones.. skin and soft tissue. . for example: erysipelas, abscesses, cellulitis, infected burns and wounds, mastitis.. gastrointestinal and abdominal. . for example: intra-abdominal abscesses, enterocolitis.. bone and joint. . for example: osteitis, osteomyelitis, septic arthritis, infected bursitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - ceftazidime pentahydrate, quantity: 1175 mg (equivalent: ceftazidime, qty 1000 mg) - injection, powder for - excipient ingredients: sodium carbonate - auro-ceftazidime is indicated for the treatment of single and mixed infections caused by susceptible aerobic organisms with suspected or documented resistance to other antimicrobials, but not to ceftazidime; as an alternative to aminoglycosides in pseudomonal infection in patients in whom aminoglycoside toxicity is a cause for concern and other antipseudomonal antibiotics cannot be used. . indications include the following.. severe infections in general. for example: septicaemia (including neonatal sepsis), bacteraemia; in patients in intensive care units with specific problems, e.g. infected burns.. respiratory tract. for example: pneumonia, bronchopneumonia, infected pleurisy, infected bronchiectasis and bronchitis.. severe ear, nose and throat infections. for example: otitis media, mastoiditis.. urinary tract. for example: acute and chronic pyelonephritis, pyelitis, cystitis, urethritis (bacterial only); infections associated with bladder and renal stones.. skin and soft tissue. . for example: erysipelas, abscesses, cellulitis, infected burns and wounds, mastitis.. gastrointestinal and abdominal. . for example: intra-abdominal abscesses, enterocolitis.. bone and joint. . for example: osteitis, osteomyelitis, septic arthritis, infected bursitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern xp ip pty ltd - ceftazidime pentahydrate, quantity: 2329.3 mg (equivalent: ceftazidime, qty 2 g) - injection, powder for - excipient ingredients: sodium carbonate; carbon dioxide - treatment of single and mixed infections caused by susceptible aerobic organisms with suspected or documented resistance to other antimicrobials, but not to ceftazidime; as an alternative to aminoglycosides in pseudomonal infection in patients in whom aminoglycoside toxicity is a cause for concern and other antipseudomonal antibiotics cannot be used. indications include the following. severe infections in general. for example: septicaemia (including neonatal sepsis), bacteraemia; in patients in intensive care units with specific problems, e.g. infected burns. respiratory tract. eg: pneumonia, bronchopneumonia, infected pleurisy, infected bronchiectasis and bronchitis. severe ear, nose and throat infections. for example: otitis media, mastoiditis. urinary tract. for example: acute and chronic pyelonephritis, pyelitis, cystitis, urethritis (bacterial only); infections associated with bladder and renal stones. skin and soft tissue. for example: erysipelas, abscesses, cellulitis, infected burns and wounds, mastitis. gastrointestinal and abdominal. for example: intra-abdominal abscesses, enterocolitis. bone and joint. for example: osteitis, osteomyelitis, septic arthritis, infected bursitis.

Philippines - English - FDA (Food And Drug Administration)

hospira phils inc - ceftazidime (as pentahydrate) - sterile powder for injection im / iv - 1g

Philippines - English - FDA (Food And Drug Administration)

qualifirst health inc - ceftazidime (as pentahydrate) with sodium carbonate - powder for injection - 1g

Philippines - English - FDA (Food And Drug Administration)

2 world traders subic, inc - ceftazidime (as pentahydrate) - powder for injection im/iv - 1 g

Israel - English - Ministry of Health

vitamed pharmaceutical industries ltd - ceftazidime as pentahydrate - powder for solution for inj/inf - ceftazidime as pentahydrate 2 g/vial - ceftazidime - ceftazidime-vit 2 g is indicated for the treatment of the infections listed below in adults and children including neonates (from birth).•nosocomial pneumonia•broncho-pulmonary infections in cystic fibrosis•bacterial meningitis•chronic suppurative otitis media•malignant otitis externa•complicated urinary tract infections•complicated skin and soft tissue infections•complicated intra-abdominal infections•bone and joint infections•peritonitis associated with dialysis in patient on capd.treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above. ceftazidime vit 2 g may be used in the management of neutropenic patients with fever that is suspected to be due to abacterial infection. ceftazidime vit 2 g may be used in the peri-operative prophylaxis of urinary tract infections for patients undergoing trans-urethral resection of the prostate (turp). the selection of ceftazidime should take into account its antibacterial spectrum, which is mainly restricted to aerobic gram negative bacteria. ceftazidime vit 2 g should be co-administered with other antibacterial agents whenever the possible range of causive bacteria would not fall within its spectrum of activity. consideration should be given to official guidelines on the appropriate use of antibacterial agents.